|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/15/18 British American Tobacco p.l.c. 20-F 12/31/17 233:140M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual Report by a Foreign Non-Canadian Issuer HTML 6.02M
2: EX-2.4 Plan of Acquisition, Reorganization, Arrangement, HTML 736K
Liquidation or Succession
3: EX-2.5 Plan of Acquisition, Reorganization, Arrangement, HTML 164K
Liquidation or Succession
4: EX-2.7 Plan of Acquisition, Reorganization, Arrangement, HTML 112K
Liquidation or Succession
5: EX-4.12 Instrument Defining the Rights of Security Holders HTML 128K
6: EX-4.13 Instrument Defining the Rights of Security Holders HTML 128K
7: EX-4.14 Instrument Defining the Rights of Security Holders HTML 128K
8: EX-4.15 Instrument Defining the Rights of Security Holders HTML 128K
9: EX-4.16 Instrument Defining the Rights of Security Holders HTML 128K
10: EX-4.17 Instrument Defining the Rights of Security Holders HTML 128K
11: EX-4.18 Instrument Defining the Rights of Security Holders HTML 128K
12: EX-4.19 Instrument Defining the Rights of Security Holders HTML 127K
13: EX-4.20 Instrument Defining the Rights of Security Holders HTML 127K
14: EX-4.21 Instrument Defining the Rights of Security Holders HTML 127K
17: EX-13 Annual or Quarterly Report to Security Holders HTML 67K
15: EX-11 Statement re: Computation of Earnings Per Share HTML 71K
16: EX-12 Statement re: Computation of Ratios HTML 79K
18: EX-15 Letter re: Unaudited Interim Financial Info HTML 67K
25: R1 Document and Entity Information HTML 94K
26: R2 Group Income Statement HTML 126K
27: R3 Group Income Statement (Parenthetical) HTML 70K
28: R4 Group Statement of Comprehensive Income HTML 147K
29: R5 Group Statement of Changes in Equity HTML 123K
30: R6 Group Balance Sheet HTML 177K
31: R7 Group Cash Flow Statement HTML 166K
32: R8 Accounting policies HTML 150K
33: R9 Segmental analyses HTML 1.91M
34: R10 Profit from operations HTML 460K
35: R11 Net finance costs/(Income) HTML 231K
36: R12 Associates and joint ventures HTML 838K
37: R13 Taxation on ordinary activities HTML 531K
38: R14 Earnings per share HTML 1.73M
39: R15 Dividends and other appropriations HTML 305K
40: R16 Intangible assets HTML 745K
41: R17 Property, plant and equipment HTML 654K
42: R18 Investments in associates and joint ventures HTML 303K
43: R19 Retirement benefit schemes HTML 2.46M
44: R20 Deferred tax HTML 405K
45: R21 Trade and other receivables HTML 238K
46: R22 Available-for-sale investments HTML 139K
47: R23 Derivative financial instruments HTML 923K
48: R24 Inventories HTML 106K
49: R25 Cash and cash equivalents HTML 172K
50: R26 Capital and reserves - reconciliation of movement HTML 4.34M
in total equity
51: R27 Borrowings HTML 1.15M
52: R28 Provisions for liabilities HTML 411K
53: R29 Trade and other payables HTML 150K
54: R30 Financial instruments and risk management HTML 587K
55: R31 Business combinations, disposals and other changes HTML 146K
in the Group
56: R32 Share-based payments HTML 613K
57: R33 Group employees HTML 132K
58: R34 Related party disclosures HTML 788K
59: R35 Contingent liabilities and financial commitments HTML 513K
60: R36 Interests in subsidiaries HTML 278K
61: R37 Condensed consolidating financial information HTML 5.89M
62: R38 Accounting policies (Policies) HTML 196K
63: R39 Segmental analyses (Tables) HTML 1.91M
64: R40 Profit from operations (Tables) HTML 441K
65: R41 Net Finance Costs/(Income) (Tables) HTML 224K
66: R42 Associates and joint ventures (Tables) HTML 831K
67: R43 Taxation on ordinary activities (Tables) HTML 522K
68: R44 Earnings per share (Tables) HTML 1.73M
69: R45 Dividends and other appropriations (Tables) HTML 302K
70: R46 Intangible assets (Tables) HTML 735K
71: R47 Property, plant and equipment (Tables) HTML 654K
72: R48 Investments in associates and joint ventures HTML 302K
(Tables)
73: R49 Retirement Benefit Schemes (Tables) HTML 2.44M
74: R50 Deferred tax (Tables) HTML 397K
75: R51 Trade and Other Receivables (Tables) HTML 239K
76: R52 Available-for-sale investments (Tables) HTML 137K
77: R53 Derivative Financial Instruments (Tables) HTML 921K
78: R54 Inventories (Tables) HTML 104K
79: R55 Cash and cash equivalents (Tables) HTML 174K
80: R56 Capital and reserves - reconciliation of movement HTML 4.34M
in total equity (Tables)
81: R57 Borrowings (Tables) HTML 1.16M
82: R58 Provisions for liabilities (Tables) HTML 404K
83: R59 Trade and other payables (Tables) HTML 147K
84: R60 Financial instruments and risk management (Tables) HTML 554K
85: R61 Business combinations, disposals and other changes HTML 129K
in the Group (Tables)
86: R62 Share-based Payments (Tables) HTML 611K
87: R63 Group Employees (Tables) HTML 128K
88: R64 Related Party Disclosures (Tables) HTML 784K
89: R65 Contingent liabilities and financial commitments HTML 291K
(Tables)
90: R66 Interests in subsidiaries (Tables) HTML 274K
91: R67 Condensed consolidating financial information HTML 5.89M
(Tables)
92: R68 Accounting policies - Additional Information HTML 99K
(Details)
93: R69 Segmental Analyses - Disclosure of Revenues at HTML 129K
Current Rates and Revenues Translated (Details)
94: R70 Segmental Analyses - Additional Information HTML 104K
(Details)
95: R71 Segmental Analyses - Disclosure of Operating HTML 217K
Segment Information (Details)
96: R72 Segmental Analyses - Summary of Depreciation HTML 132K
Amortisation and Impairment Charges (Details)
97: R73 Segmental Analyses - Disclosure of Geographical HTML 84K
Information of External Revenue (Details)
98: R74 Profit from Operations - Summary of Employee HTML 79K
Benefit Costs (Details)
99: R75 Profit from Operations - Summary of Depreciation HTML 81K
Amortisation and Impairment Costs (Details)
100: R76 Profit from Operations - Summary of Other HTML 110K
Operating Expenses (Details)
101: R77 Profit from Operations - Other Operating Expenses HTML 94K
- Additional Information (Details)
102: R78 Profit from Operations - Master Settlements HTML 81K
Agreement - Additional Information (Details)
103: R79 Profit from Operations - Summary Costs of HTML 85K
Integrating Acquired Businesses into Existing
Operations (Details)
104: R80 Profit from Operations - Restructuring and HTML 75K
Integration Costs - Additional Information
(Details)
105: R81 Profit from Operations - Fox River - Additional HTML 100K
Information (Details)
106: R82 Profit from Operations - Other Adjusting Items - HTML 81K
Additional Information (Details)
107: R83 Profit from Operations - Flintkote - Additional HTML 72K
Information (Details)
108: R84 Net Finance Costs/(Income) - Summary of Net HTML 101K
Finance Costs/(Income) (Details)
109: R85 Net Finance Costs/(Income) - Additional HTML 94K
Information (Details)
110: R86 Associates and Joint Ventures - Schedule of Profit HTML 122K
Loss of Associates and Joint Ventures Accounted
for Using Equity Method (Details)
111: R87 Associates and Joint Ventures - Additional HTML 142K
Information (Details)
112: R88 Associates and Joint Ventures - Summary of Group's HTML 89K
Share of the Result of Associates and Joint
Ventures (Details)
113: R89 Associates and Joint Ventures - Summary of HTML 109K
Financial Information of the Group's Associates
and Joint Ventures (Details)
114: R90 Taxation on Ordinary Activities - Summary of HTML 93K
Taxation on Ordinary Activities (Details)
115: R91 Taxation on Ordinary Activities - Additional HTML 119K
Information (Details)
116: R92 Taxation on Ordinary Activities - Summary of HTML 139K
Factors Affecting the Taxation Charge (Details)
117: R93 Taxation on Ordinary Activities - Summary of HTML 73K
Factors Affecting the Taxation Charge
(Parenthetical) (Details)
118: R94 Taxation on Ordinary Activities - Summary of Tax HTML 75K
on Items Recognised Directly in Other
Comprehensive Income (Details)
119: R95 Earnings Per Share - Summary of Earnings Per Share HTML 87K
(Details)
120: R96 Earnings Per Share - Summary of Earnings Per Share HTML 69K
(Parenthetical) (Details)
121: R97 Earnings Per Share - Summary of Adjusted Earnings HTML 243K
Per Share (Details)
122: R98 Earnings Per Share - Summary of Headline Earnings HTML 183K
Per Share (Details)
123: R99 Dividends and Other Appropriations - Summary of HTML 74K
Detailed Information About Dividends (Details)
124: R100 Dividends and Other Appropriations - Additional HTML 81K
Information (Details)
125: R101 Intangible Assets - Schedule of Movement In HTML 121K
Intangible Assets (Details)
126: R102 Intangible Assets - Additional Information HTML 153K
(Details)
127: R103 Intangible Assets - Schedule of Cash Generating HTML 102K
Unit (Details)
128: R104 Property, Plant and Equipment - Schedule of HTML 133K
Property, Plant and Equipment (Details)
129: R105 Property, Plant and Equipment - Additional HTML 82K
Information (Details)
130: R106 Property, Plant and Equipment - Schedule of Cost HTML 87K
of Freehold Land, Net Book Value of Leasehold
Properties and Contracts Placed for Future
Expenditure (Details)
131: R107 Investments in Associates and Joint Ventures - HTML 123K
Summary of Investments In Associates And Joint
Ventures (Details)
132: R108 Investments in Associates and Joint Ventures - HTML 78K
Summary of Investments In Associates And Joint
Ventures (Parenthetical) (Details)
133: R109 Investments in Associates and Joint Ventures - HTML 105K
Additional Information (Details)
134: R110 Investments in Associates and Joint Ventures - HTML 93K
Summary of Principal Associate Undertakings
(Details)
135: R111 Investments in Associates and Joint Ventures - HTML 75K
Summary of Principal Associate Undertakings
(Parenthetical) (Details)
136: R112 Investments in Associates and Joint Ventures - HTML 100K
Summary of Latest Published Information (Details)
137: R113 Investments in Associates and Joint Ventures - HTML 72K
Summary of Latest Published Information
(Parenthetical) (Details)
138: R114 Retirement Benefit Schemes - Additional HTML 174K
Information (Details)
139: R115 Retirement Benefit Schemes - Schedule of Defined HTML 105K
Benefit Amounts Recognised in Balance Sheets
(Details)
140: R116 Retirement Benefit Schemes - Schedule of Defined HTML 80K
Net Liability Recognised in Balance Sheets
(Details)
141: R117 Retirement Benefit Schemes - Schedule of Net HTML 100K
Liabilities of Funded Pension Schemes by Territory
(Details)
142: R118 Retirement Benefit Schemes - Schedule of Defined HTML 94K
Benefit Amounts Recognised in Income Statement
(Details)
143: R119 Retirement Benefit Schemes - Schedule of Movements HTML 112K
in Scheme Liabilities (Details)
144: R120 Retirement Benefit Schemes - Schedule of Scheme HTML 87K
Liabilities by Scheme Membership (Details)
145: R121 Retirement Benefit Schemes - Summary of Movements HTML 123K
in Funded Scheme Assets (Details)
146: R122 Retirement Benefit Schemes - Summary of Movements HTML 81K
in the Unrecognised Scheme Surpluses Recognised in
Other Comprehensive Income (Details)
147: R123 Retirement Benefit Schemes - Summary of Actuarial HTML 103K
Assumptions Rate for Valuations Plans (Details)
148: R124 Retirement Benefit Schemes - Summary of Principal HTML 83K
Schemes Used (Details)
149: R125 Retirement Benefit Schemes - Summary of Weighted HTML 93K
Average Life Expectancy Used to Determine Benefit
Obligations (Details)
150: R126 Retirement Benefit Schemes - Summary of HTML 81K
Sensitivity Analysis (Details)
151: R127 Deferred Tax - Summary of Reconciliation of Net HTML 114K
Deferred Tax Assets/(Liabilities) (Details)
152: R128 Deferred Tax - Additional Information (Details) HTML 116K
153: R129 Trade and Other Receivables - Summary of Trade and HTML 83K
Other Receivables (Details)
154: R130 Trade and Other Receivables - Additional HTML 88K
Information (Details)
155: R131 Trade and Other Receivables - Summary of Trade and HTML 75K
Other Receivables Reported in Balance Sheet Net of
Allowances (Details)
156: R132 Trade and Other Receivables - Summary of Movements HTML 79K
in Allowance Account (Details)
157: R133 Trade and Other Receivables - Summary of Aged HTML 82K
Analysis of Trade Receivables (Details)
158: R134 Available-for-sale Investments - Schedule of HTML 88K
Available-for-sale Investments (Details)
159: R135 Derivative Financial Instruments - Summary of HTML 110K
Derivatives (Details)
160: R136 Derivative Financial Instruments - Additional HTML 79K
Information (Details)
161: R137 Derivative Financial Instruments - Summary of HTML 100K
Maturity Dates of Gross-settled Derivative
Financial Instruments (Details)
162: R138 Derivative Financial Instruments - Summary of HTML 88K
Maturity Dates of Net-settled Derivative Financial
Instruments (Details)
163: R139 Inventories - Summary of Inventories (Details) HTML 76K
164: R140 Inventories - Additional Information (Details) HTML 73K
165: R141 Cash and Cash Equivalents - Schedule Representing HTML 75K
Cash and Cash Equivalents (Details)
166: R142 Cash and Cash Equivalents - Summary of Cash and HTML 79K
Cash Equivalents Denominated in the Functional
Currency of the Subsidiary Undertaking or Other
Currencies (Details)
167: R143 Cash and Cash Equivalents - Summary of Net Cash HTML 76K
and Cash Equivalents Shown After Deducting Bank
Overdrafts and Accrued Interest (Details)
168: R144 Cash and Cash Equivalents - Additional Information HTML 70K
(Details)
169: R145 Capital and Reserves - Reconciliation of Movement HTML 214K
in Total Equity - Summary of Capital and Reserves
- Reconciliation of Movement in Total Equity
(Details)
170: R146 Capital and Reserves - Reconciliation of Movement HTML 83K
in Total Equity - Summary of Composition of Share
Premium Account, Capital Redemption Reserves and
Merger Reserves (Details)
171: R147 Capital and Reserves - Reconciliation of Movement HTML 136K
in Total Equity - Additional Information (Details)
172: R148 Capital and Reserves - Reconciliation of Movement HTML 83K
in Total Equity - Summary of Movements of Called
Up Share Capital (Details)
173: R149 Capital and Reserves - Reconciliation of Movement HTML 72K
in Total Equity - Summary of Movements of Called
Up Share Capital (Parenthetical) (Details)
174: R150 Capital and Reserves - Reconciliation of Movement HTML 201K
in Total Equity - Summary of Movements in Other
Reserves and Retained Earnings (Details)
175: R151 Capital and Reserves - Reconciliation of Movement HTML 90K
in Total Equity - Summary of Tax Attributable to
Components of Other Comprehensive Income (Details)
176: R152 Borrowings - Schedule of Detailed Information HTML 129K
About Borrowings (Details)
177: R153 Borrowings - Additional Information (Details) HTML 118K
178: R154 Borrowings - Schedule of Detailed Information HTML 92K
About Repayment of Borrowings (Details)
179: R155 Borrowings - Schedule of Analysis of Borrowings by HTML 105K
Currency (Details)
180: R156 Borrowings - Schedule of Analysis of Borrowings by HTML 112K
Interest Rate Changes (Details)
181: R157 Borrowings - Schedule of Analysis of Net Debt HTML 81K
(Details)
182: R158 Borrowings - Schedule of Analysis of Net Debt HTML 71K
(Parenthetical) (Details)
183: R159 Borrowings - Schedule of Analysis of Net Debt HTML 92K
Movements (Details)
184: R160 Provisions for liabilities - Summary of Provisions HTML 101K
Excluding Post-Retirement Benefits (Details)
185: R161 Provisions for liabilities - Additional HTML 100K
Information (Details)
186: R162 Trade and Other Payables - Summary of Trade and HTML 86K
Other Payables (Details)
187: R163 Trade and Other Payables - Additional Information HTML 76K
(Details)
188: R164 Financial Instruments and Risk Management - HTML 300K
Additional Information (Details)
189: R165 Financial Instruments and Risk Management - HTML 99K
Summary of Assets and Liabilities Measured at Fair
Value (Details)
190: R166 Financial Instruments and Risk Management - HTML 79K
Summary of Derivative Financial Asset and
Liabilities Offsetting Arrangements (Details)
191: R167 Business Combinations, Disposals and Other Changes HTML 293K
in the Group - Additional Information (Details)
192: R168 Business Combinations, Disposals and Other Changes HTML 116K
in the Group - Schedule of Fair Values Assigned to
the Asset Acquired and Liabilities Assumed on
Acquisition Date (Details)
193: R169 Business Combinations, Disposals and Other Changes HTML 76K
in the Group - Schedule of Fair Values Assigned to
the Asset Acquired and Liabilities Assumed on
Acquisition Date (Parenthetical) (Details)
194: R170 Share-based Payments - Additional Information HTML 152K
(Details)
195: R171 Share-based Payments - Summary of Share-based HTML 88K
Payment Expense (Details)
196: R172 Share-based Payments - Summary of Share-based HTML 84K
Payment Liability (Details)
197: R173 Share-based Payments - Summary of Movements for HTML 89K
Equity and Cash-Settled LTIP Scheme (Details)
198: R174 Share-based Payments - Summary of Movements for HTML 88K
Equity and Cash-Settled DSBS Scheme (Details)
199: R175 Share-based Payments - Valuation Assumptions HTML 88K
(Details)
200: R176 Share-based Payments - Summary of Valuation HTML 73K
Assumptions Used in Models (Details)
201: R177 Group Employees - Additional Information (Details) HTML 70K
202: R178 Group Employees - Summary of Average Number of HTML 85K
Persons Employed by Group and Associates (Details)
203: R179 Related Party Disclosures - Additional information HTML 121K
(Details)
204: R180 Related Party Disclosures - Summary of HTML 81K
Transactions Between Related Parties (Details)
205: R181 Related Party Disclosures - Summary of Amounts HTML 114K
Incurred by Entity for Provision of Key Management
Personnel Services (Details)
206: R182 Related Party Disclosures - Summary of Aggregate HTML 96K
Gains on LTIP Shares Exercised (Details)
207: R183 Related Party Disclosures - Summary of Aggregate HTML 74K
Gains on LTIP Shares Exercised (Parenthetical)
(Details)
208: R184 Contingent Liabilities and Financial Commitments - HTML 74K
General Litigation Overview - Additional
Information (Details)
209: R185 Contingent Liabilities and Financial Commitments - HTML 173K
US Litigation - Additional Information (Details)
210: R186 Contingent Liabilities and Financial Commitments - HTML 152K
Engle Class Action and Engle Progeny Cases -
Additional Information (Details)
211: R187 Contingent Liabilities and Financial Commitments - HTML 83K
Summary of Engle Progeny Cases (Details)
212: R188 Contingent Liabilities and Financial Commitments - HTML 86K
Summary of Engle Progeny Cases (Parenthetical)
(Details)
213: R189 Contingent Liabilities and Financial Commitments - HTML 87K
Summary of Individual Cases (Details)
214: R190 Contingent Liabilities and Financial Commitments - HTML 115K
Summary of Individual Cases (Parenthetical)
(Details)
215: R191 Contingent Liabilities and Financial Commitments - HTML 81K
Operating Subsidiaries' Expenses and Payments
under State Settlement Agreements (Details)
216: R192 Contingent Liabilities and Financial Commitments - HTML 214K
Product Liability Outside the United States -
Additional Information (Details)
217: R193 Contingent Liabilities and Financial Commitments - HTML 110K
Summary of Current Status of Litigation Cases
(Details)
218: R194 Contingent Liabilities and Financial Commitments - HTML 209K
Non-Tobacco Related Litigation - Additional
Information (Details)
219: R195 Contingent Liabilities and Financial Commitments - HTML 88K
Closed Litigation Matters Explanatory (Details)
220: R196 Contingent Liabilities and Financial Commitments - HTML 83K
Other contingencies - Additional Information
(Details)
221: R197 Contingent Liabilities and Financial Commitments - HTML 87K
Tax Disputes - Additional Information (Details)
222: R198 Contingent Liabilities and Financial Commitments - HTML 84K
Schedule of Total Future Minimum Lease Payments
under Non-cancellable Operating Leases (Details)
223: R199 Contingent Liabilities and Financial Commitments - HTML 76K
Performance Guarantees - Additional Information
(Details)
224: R200 Interests in Subsidiaries - Additional Information HTML 87K
(Details)
225: R201 Interests in Subsidiaries - Summary of Financial HTML 143K
Information of Subsidiaries with Material
Non-controlling Interests (Details)
226: R202 Condensed consolidating financial information - HTML 73K
Additional Information (Details)
227: R203 Condensed consolidating financial information - HTML 166K
Condensed Consolidated Income Statement (Details)
228: R204 Condensed consolidating financial information - HTML 156K
Condensed Consolidated Statement of Comprehensive
Income (Details)
229: R205 Condensed consolidating financial information - HTML 257K
Condensed Consolidated Balance Sheet (Details)
230: R206 Condensed consolidating financial information - HTML 116K
Condensed Consolidated Cash Flow Statement
(Details)
232: XML IDEA XML File -- Filing Summary XML 455K
231: EXCEL IDEA Workbook of Financial Reports XLSX 337K
19: EX-101.INS XBRL Instance -- bti-20171231 XML 58.91M
21: EX-101.CAL XBRL Calculations -- bti-20171231_cal XML 666K
22: EX-101.DEF XBRL Definitions -- bti-20171231_def XML 3.36M
23: EX-101.LAB XBRL Labels -- bti-20171231_lab XML 4.32M
24: EX-101.PRE XBRL Presentations -- bti-20171231_pre XML 4.15M
20: EX-101.SCH XBRL Schema -- bti-20171231 XSD 973K
233: ZIP XBRL Zipped Folder -- 0001193125-18-083410-xbrl Zip 1.27M
| EX-4.17 |
Exhibit 4.17
24 July 2017
STRICTLY PRIVATE & CONFIDENTIAL
ADDRESSEE ONLY
Dr Pedro Malan
[Address]
Dear Dr Malan
Letter of Appointment
Pursuant to clause 1.1 of your letter of appointment dated 25 April 2017, I am pleased to confirm the revised terms applicable to your appointment as a Non-Executive Director of the Company (the “Appointment”), which are conditional upon, and will take effect from, the successful completion of the BAT Group’s proposed acquisition of Reynolds American Inc. (expected to occur on 25 July 2017).
| 1. | TERM OF APPOINTMENT |
| 1.1 | Your Appointment took effect from the close of the Company’s Annual General Meeting on 26 April 2017 and will continue, pursuant to the terms of this letter, until the close of the Company’s next Annual General Meeting in 2018 (the “Next AGM”) (the “Appointment Period”) unless the Appointment is terminated in accordance with paragraph 10 below. |
| 1.2 | Your tenure as a Non-Executive Director of the Company commenced on your original date of appointment as a Director which was 2 February 2015. |
| 1.3 | For the avoidance of doubt, the Appointment is one of officeholder and not of employment and neither the Company nor you shall hold you out as an employee of the BAT Group. |
| 2. | DUTIES |
Time Commitment
| 2.1 | You will be expected to devote such time as is necessary for the proper performance of your duties. We expect to hold six Board meetings per calendar year. We arrange committee meetings, strategy sessions, Board dinners and AGMs around these meetings and so it is best to anticipate a time commitment of two days per meeting. In addition, you will be expected to devote appropriate preparation time ahead of each meeting and be prepared for at least one site visit per year, which may be at an overseas location. You may also be required to attend meetings as part of the annual Board evaluation process and update meetings and training sessions. You will therefore be expected to make an annual time commitment of between 25 and 30 days, subject to the circumstances and level of activities of the Company. Ad hoc matters may arise from time to time and particularly when the Company is undergoing increased activity. It may be therefore necessary to convene additional Board, Committee or other meetings. If business must be transacted between regular Board meetings, you will be advised. Copies of the current Board programmes are available from the Company Secretary. |
It is expected that you will attend the meetings outlined above unless urgent prior commitments, or unavoidable circumstances, prevent you from doing so. Attendance at meetings by way of telephone conference call may be possible, subject to the Chairman’s
1
consent.
By accepting the Appointment, you confirm that you can allocate sufficient time to meet the expectations of your role. The prior agreement of the Chairman should be sought before accepting additional commitments that might affect the time you can devote to your role as a Non-Executive Director of the Company.
Role
| 2.2 | As a Non-Executive Director of the Company you will have the same general legal responsibilities to the Company as any other Director, together with such specific duties as may be agreed with the Board and which relate to the business of the Company or any other member of the BAT Group. The Board is collectively responsible for promoting the success of the Company by directing and supervising the Company’s affairs. |
The role of the Non-Executive Director has the following key elements:
| • | Strategy: Non-Executive Directors should constructively challenge and contribute to the development of strategy; |
| • | Performance: Non-Executive Directors should scrutinize the performance of management in meeting agreed goals and objectives and monitor the reporting of performance; |
| • | Risk: Non-Executive Directors should satisfy themselves that financial information is accurate and that financial controls and systems of risk management are robust and defensible; and |
| • | People: the Remuneration Committee, populated by Non-Executive Directors, is responsible for determining appropriate levels of remuneration of Executive Directors and the Nominations Committee (also populated by Non-Executive Directors) has a prime role in appointing, and where necessary removing, senior management and in succession planning. |
| 2.3 | During the continuance of the Appointment you shall: |
| 2.3.1 | promote the success of the Company for the benefit of its members as a whole and comply with the directors’ duties set out in Part 10 of the Companies Act 2006; |
| 2.3.2 | faithfully, efficiently, competently and diligently perform your duties and exercise such powers as are appropriate to your role as a Non-Executive Director; |
| 2.3.3 | in so far as reasonably possible, attend all meetings of the Board and of the committees of the Board of which you are a member or to which you may be invited to attend from time to time; |
| 2.3.4 | promptly declare, so far as you are aware, the nature of any interest, whether direct or indirect, in accordance with paragraph 5.5 below; |
| 2.3.5 | observe and comply with all relevant regulations impacting the Company as may apply from time to time. These include the City Code on Take Overs and Mergers; the Listing Rules; the Disclosure Guidance and Transparency Rules; the Prospectus Rules and the UK Corporate Governance Code; the EU Market Abuse Regulation and Implementing Regulations; the British American Tobacco p.l.c. Code for Share Dealing from time to time in force in relation to dealing in shares, debentures and other securities of the Company and inside information |
2
| affecting the shares, debentures or other securities of the Company; applicable US Securities, Listing and Anti-Bribery Laws and Regulations; and applicable corporate governance and regulatory requirements in South Africa, including the JSE Listing Requirements; |
| 2.3.6 | comply personally with the Company’s rules and policies on corporate governance and its Standards of Business Conduct from time to time in force and use all reasonable endeavours to ensure that the BAT Group (as appropriate) so complies; |
| 2.3.7 | comply with all reasonable requests, instructions and regulations made or given by the Board (or by any duly authorised committee thereof) and give to the Board such explanations, information and assistance as the Board may reasonably require; and |
| 2.3.8 | use your reasonable endeavours to promote and extend the interests and reputation of the BAT Group, including assisting the Chairman and the Board in relation to public and corporate affairs and bringing to bear, for the benefit of the Chairman and the Board, your specialist knowledge and experience. |
In addition, you should devote time to developing and refreshing your knowledge and skills, uphold high standards of integrity and probity, support the Chairman and promote amongst the other Directors an appropriate culture and set of values and behaviours in the boardroom and beyond and take into account the views of shareholders and other stakeholders where appropriate.
| 2.4 | If there are matters which arise which cause you concern about your role you should discuss them with the Chairman or the Senior Independent Director. If you have any concerns which cannot be resolved, and you choose to resign for that, or any other reason, you should provide an appropriate written statement to the Chairman or the Senior Independent Director for circulation to the Board. |
Committees
| 2.5 | You will continue to be a member of the Nominations Committee and the Audit Committee. Should you also be appointed as a member of additional Board Committees, such appointment will be confirmed to you in a supplemental letter to this letter of appointment or in a revised letter of appointment. The ambit and main terms of reference of the Board Committees are described in the British American Tobacco Corporate Governance booklet, a copy of which is available from the Company Secretary. |
| 3. | FEES AND EXPENSES |
| 3.1 | Your base fee (Base Fee) is set at the rate of £92,700 per annum less any deductions which the Company may be required to make including in respect of tax and national insurance contributions. The Base Fee is payable in arrears by twelve equal monthly instalments. The fees for Non-Executive Directors are reviewed annually. |
| 3.2 | With reference to paragraph 2.5 above, you are entitled to an additional fee of £11,000 per annum per Committee (a Committee Membership Fee). Should you be appointed as Chair of a Committee of the Board, you will be entitled to an additional annual fee at the rate agreed with reference to the Board from time to time. |
A Committee Membership Fee and any other additional fees or payments will be made less any deductions which the Company may be required to make including in respect of tax
3
and national insurance contributions. These additional fees and payments are also payable in arrears by twelve equal monthly instalments.
| 3.3 | Subject to the Articles, the Company shall reimburse to you all travel, hotel and other expenses reasonably incurred by you in the proper performance of your obligations under this letter provided that you supply receipts or other evidence of expenditure. |
| 3.4 | The Company will meet, as appropriate, any personal income tax liability that arises from any benefits provided or paid for by the Company. |
| 4. | INDEPENDENT PROFESSIONAL ADVICE |
| 4.1 | Your expenses may include legal fees if it is necessary, in the furtherance of your duties, for you to seek independent legal advice (provided that allegations of negligence, breach of duty or bad faith have not been made against you). Accordingly, the Board has approved a procedure for taking independent advice in such circumstances. Any such payment by the Company would, of course, be subject to any applicable restriction under company law. |
| 4.2 | Further to clause 4.1 above, the advice and services of the Company Secretary, and the Director, Legal & External Affairs and General Counsel, are available to each Director for guidance on the Director’s responsibilities and those of the Board and in relation to any specific activity or transaction of the Company. |
| 4.3 | It is also recognised that there may be occasions when you may need to have independent professional advice in connection with the performance of your duties as a Director of the Company and that this should be paid for by the Company. In such an instance, you should first refer the matter to the Company Secretary. This will avoid you seeking advice from a source where there is a conflict of interest (for example, because that firm is or has been an adviser to a competitor company) or where it would be inappropriate for other reasons (for example, because the firm has acted for the Company or its subsidiaries). |
| 5. | PROTECTION OF THE BAT GROUP AND CONFLICTS OF INTEREST |
| 5.1 | You will not, for the Restricted Period in the Restricted Area, directly or indirectly (a) hold office in, (b) be employed by, (c) provide services to or (d) be otherwise interested in, any company, firm or other business entity which is engaged in Restricted Business otherwise than with the prior written permission of the Board. |
“Restricted Period” means the (a) duration of the Appointment plus (b) a period of three months immediately following the ending of the Appointment.
“Restricted Area” means any country in the world in which any BAT Group Company either (a) is engaged in Restricted Business or (b) proposes to be engaged in Restricted Business within twelve months immediately following the end of the Appointment.
“Restricted Business” means (a) the manufacture, sale or distribution of tobacco products and/or (b) Next Generation Products and/or (c) any other products or services offered by any subsidiary in the BAT Group as at the end of the Restricted Period.
| 5.2 | You will not, without the Board’s prior written consent (which shall not be unreasonably withheld), (a) hold office in, (b) be employed by, or (c) provide services to any company, firm, or other business entity during the term of your Appointment. |
4
| 5.3 | You undertake that during the term of your Appointment you will: |
| 5.3.1 | promptly disclose to the Board in writing any proposed new directorship or appointment together with any subsequent confirmation that the appointment is effective and any changes to such directorship or appointment; |
| 5.3.2 | promptly disclose to the Board in writing any prior existing interests in a company, business or undertaking which competes with or is a customer of or a supplier to any company within the BAT Group (“competing interest”); and |
| 5.3.3 | not acquire any new competing interest. |
| 5.4 | Your attention is drawn to the procedures established for managing compliance with the conflict of interest provisions of the Companies Act 2006. Under these provisions: |
| 5.4.1 | you may not allow any situation to arise in which you will have, or may have, a direct or indirect interest that conflicts, or possibly may conflict, with the interests of the Company (a situational conflict), unless the matter has been authorised in advance by the Board; and |
| 5.4.2 | you must declare in advance any interest in a proposed transaction or arrangement with the Company (a transactional conflict). |
| 5.5 | You are required to give advance notice of any situational or transactional conflict to the Company Secretary and any such matter will be considered either at the next Board meeting or, if the conflict or potential conflict is due to arise prior to the next scheduled Board meeting, at a meeting of the Conflicts Committee. |
| 5.6 | Subject to compliance with the provisions of the Group’s Standards of Business Conduct with regard to real, potential or perceived conflicts of interest, in particular, the provisions relating to financial interests, this paragraph 5 shall not prevent you from holding for investment purposes an interest (as defined in S.820 – 825 of the Companies Act 2006) of up to 5% in nominal value or (in the case of securities not having any nominal value) in number or class of securities, in any class of securities in a company which is quoted on any Investment Exchange, as recognised by the FCA. For this purpose, the references to securities held by you include securities beneficially held by your immediate family. |
| 6. | CONFIDENTIALITY |
| 6.1 | You will not either during the period of the Appointment or after its termination (without limitation in time) directly or indirectly (including, without limitation, via social media) disclose to any person or organisation, or use, any trade secrets or Confidential Information belonging, or relating, to the business of the BAT Group. This obligation shall not apply in the following circumstances: |
| 6.1.1 | where its disclosure or use is necessary for the proper discharge of your duties the Appointment; or |
| 6.1.2 | where such trade secrets or confidential information have entered the public domain, other than by way of unauthorised disclosure whether by you or a third party; or |
| 6.1.3 | such disclosure is permitted by the Public Interest Disclosure Act 1998, as amended. |
| 6.2 | You shall not at any time during the continuance of the Appointment make any notes or memoranda relating to any matter within the scope of the Company’s business, dealings |
5
| or affairs otherwise than for the benefit of the Company or any BAT Group company. You will return all such materials in any format (including copies) on request by the Company. |
| 6.3 | The Company may, from time to time, supply to you software applications for the purposes of accessing the BAT Group information technology systems and networks and/or for the purposes of accessing the papers of the Board and its Committees through a personal device such as an iPhone or an iPad. Such use is subject to the various BAT Group Policies, Standards and Guidelines including, but not limited to, the Acceptable Use Policy and the IT Security Policy Statement in place from time to time. The terms and conditions and use of these software applications are hereby incorporated by reference into this letter of appointment. |
| 7. | INDEMNITY |
| 7.1 | Subject to clause 7.2 below, the Company shall, both during the term of the Appointment and after its termination, indemnify you, keep you indemnified against and pay to you an amount equal to all costs, charges expenses, losses, damages or liabilities which you may sustain or incur in or about the execution of your duties to the Company or of any associated company of the Company or as a result of any contract, deed, matter or thing done, entered into or executed by you on behalf of any such company or in relation to the business of any such company. |
| 7.2 | The indemnity referred to in clause 7.1 shall not apply in any of the following circumstances: |
| 7.2.1 | where and to the extent that any recovery is made by you under any policy of insurance; or |
| 7.2.2 | where and to the extent that any liability is prohibited or rendered unenforceable by the Companies Acts 2006 (or any statutory modification or re-enactment thereof in force from time to time) or as otherwise prohibited by law; or |
| 7.2.3 | where the Company considers that you have acted in bad faith with wilful default or gross negligence, intentionally not in compliance with the Company’s Standards of Business Conduct Policy (as from time to time in force) (copy available from the Company Secretary) or otherwise so as to bring the Company or any of its associated companies into disrepute. |
| 7.3 | The indemnity provided in clause 7.1 shall take effect notwithstanding that the Company (or any of its associated companies) or you may have purchased and maintained insurance cover in respect of any liability, loss or expenditure incurred by any director or officer of the Company and the indemnity provided under clause 7.1 above shall be enforceable against the Company regardless of whether a claim may be made or has been pursued under such insurance. |
| 7.4 | All sums payable by the Company hereunder shall be paid free and without rights of counterclaim or set-off and without deduction and withholding on any ground whatsoever, save only as may be required by law. If any such deduction or withholding is required by law, the Company shall be obliged to pay you such amount as will ensure that, after any deduction or withholding has been made, you shall have received a sum equal to the amount that you would otherwise have received in the absence of any such deduction or withholding. |
| 7.5 | If you become aware of any notice, demand or other document issued, any claim made or action taken either before or after the date hereof which appears to you to be relevant for |
6
| the purposes of the indemnity in clause 7.1 or likely to give rise to any liability of the Company under that indemnity (hereinafter referred to as a “Demand”), you shall give notice thereof as soon as reasonably practicable. |
| 7.6 | You shall provide the Company as soon as reasonably practicable with all supporting documentation and information relating to a Demand as the Company may reasonably require. |
| 7.7 | You shall, at the request and at the expense of the Company, do and concur in doing and permit to be done all such acts and things as the Company may reasonably request to avoid, dispute, resist, appeal or compromise any Demand and you shall further make no settlement or compromise of the subject matter of any Demand, nor agree to any matter in the conduct of any dispute in relation thereto nor take any other action or omit to do any other thing in relation to any Demand without the prior written approval of the Company (such approval not to be unreasonably withheld or delayed). |
| 7.8 | The Company may, by written notice to you at any time and without prejudice to your rights of indemnification as set out in clause 7.1 above, forthwith assume (where appropriate, in your name) the conduct of any negotiations, settlement or compromise discussions or proceedings in relation to a Demand. The Company shall have full discretion in the conduct or settlement of any claim or proceedings. |
| 7.9 | You shall provide the Company as soon as reasonably practicable following any request with reasonable details of all costs and liabilities incurred by you in relation to any Demand. |
| 7.10 | The rights and obligations set out in this clause 7 shall not modify or waive any of the duties which you owe as a director or officer of the Company or any of its associated companies (as the case may be), as a matter of law or under the rules of any relevant stock exchange or regulatory body. |
| 7.11 | The Company shall, in the event that a payment is made to you under this indemnity in respect of a particular liability, be entitled to recover from you an amount equal to any payment received by you under any policy of insurance or from any other third party to the extent that such payment relates to the liability, and a deduction may similarly be made from any payment made by the Company to the extent any such payment has already been received by you. You shall pay any sum owing in accordance with the foregoing forthwith upon the Company’s request. |
| 7.12 | To the extent any payment of costs under clause 7.1 of this indemnity is treated under the Companies Act as a loan repayable to the Company, subject to the Companies Act and provided that the requirements for a qualifying third party indemnity provision are met, you shall not be required to repay the loan. |
| 7.13 | For the purposes of this clause 7, “associated company” and “qualifying third party indemnity provision” has the meaning given in Part 10 of the Companies Act 2006. |
| 8. | INSURANCE |
The Company has Directors’ and Officers’ liability insurance and it is intended to maintain such cover during the Appointment Period and thereafter as a past Director of the Company. The current programme for the Board incorporates a limit of £500 million within which £100m is reserved exclusively for Directors of the Company. A summary
7
| sheet for the period of coverage is available from the Company Secretary. |
| 9. | COMPANY’S DUTIES |
The Company shall make available to you all documents and information which you reasonably require to enable you to perform your duties under the Appointment.
| 10. | TERMINATION OF APPOINTMENT |
| 10.1 | Your appointment will terminate: |
| 10.1.1 | if the Board requests you not to offer yourself for election or re-election at the Next AGM with effect from the conclusion of the relevant AGM; or |
| 10.1.2 | forthwith, if you are not elected or re-elected at the Next AGM at which you are put forward for election or re-election; or |
| 10.1.3 | forthwith, if you are required to vacate office for any reason pursuant to any of the provisions of the Articles; or |
| 10.1.4 | forthwith, if you are removed as a Director or otherwise required to vacate office under any applicable law. |
| 10.2 | You may terminate this letter of appointment at any time during the Appointment Period in accordance with clause 85(e) of the Articles. |
| 10.3 | On termination of your appointment you will be entitled to any accrued but unpaid Director’s fees but not to any compensation. |
| 10.4 | On the termination of your appointment: |
| 10.4.1 | you will at the request of the Company (where relevant) resign (in writing) from the office of Director and you irrevocably authorise the Company as your attorney in your name and on your behalf by to sign all documents and do all things necessary to give effect to this; |
| 10.4.2 | you will surrender to an authorised representative of the Company all correspondence, documents (including without limitation Board minutes and Board papers), copies thereof or other property of the BAT Group made or received by you in the course of your directorship (whether before or after the date of this letter); and |
| 10.4.3 | you hereby agree that you shall not be entitled to and shall not pursue any action or claim for compensation from the Company whether such termination occurs before or after the date of expiry of your Appointment Period. |
| 11. | DEFINITIONS |
In this letter:
| 11.1 | “Articles” means the articles of association from time to time of the Company; |
| 11.2 | “BAT Group” means the Company, any holding company of the Company and any direct or indirect subsidiary of the Company or of any such holding company (with holding company and subsidiary having the meanings ascribed to them by the Companies Act 2006), and any other company or business entity in which the company or any other BAT Group Company owns or has a beneficial interest in 20% or more of the issued share capital or of the |
8
| capital assets; |
| 11.3 | “Board” means the board of Directors of the Company; |
| 11.4 | “Companies Act 2006” means the Companies Act 2006, as in force from time to time; |
| 11.5 | “Company” means British American Tobacco p.l.c. (Company No. 3407696); |
| 11.6 | “Confidential Information” includes confidential information relating or belonging to the Company or other BAT Group companies including but not limited to any such information relating to customers, customer lists or requirements, price lists or pricing structures, sales and marketing information, activities, business plans or dealings, employees or officers, source codes and computer systems, software, financial information and plans, designs, formulae, prototypes, product lines, services, research activities or results, any document marked ‘confidential’ (or with a similar expression), or any information which you have been told is confidential or which you might reasonably expect the Company would regard as confidential, or any information which has been given to the Company or any BAT Group company in confidence by customers, suppliers or other persons. |
| 11.7 | “Disclosure Guidance and Transparency Rules” means the Disclosure Guidance and Transparency Rules published by the FCA; |
| 11.8 | “EU Market Abuse Regulation and Implementing Regulations”, means the EU Market Abuse Regulation (EU 596/2014) together with such applicable implementation regulations as may be published and in force from time to time; |
| 11.9 | “FCA” means the Financial Conduct Authority; |
| 11.10 | “JSE Listings Requirements” means the Listings Requirements published by the JSE Limited, as may be applicable from time-to-time in respect of the secondary listing of the Company’s ordinary shares on the JSE Limited in South Africa; |
| 11.11 | “Listing Rules” means the Listing Rules published by the FCA; |
| 11.12 | “Prospectus Rules” means the Prospectus Rules published by the Financial Conduct Authority; |
| 11.13 | “UK Corporate Governance Code” means the principles of good governance published by the Financial Reporting Council being the “UK Corporate Governance Code”; and |
| 11.14 | “US Securities, Listing and Anti-Bribery Laws and Regulations” means the rules and regulations of the United States Securities and Exchange Commission and the Sarbanes Oxley Act of 2002, as amended; the New York Stock Exchange rules and listing standards; and the anti-bribery and corruption provisions of the Foreign Corrupt Practices Act of 1977, as amended. |
| 12. | MISCELLANEOUS |
| 12.1 | The various provisions and sub-provisions of this letter are severable and if any provision or sub-provision is held to be unenforceable by any court of competent jurisdiction then such unenforceability shall not affect the enforceability of the remaining provisions or sub-provisions in this Agreement. |
| 12.2 | You represent and warrant that you are not prevented by any agreement, arrangement, contract, understanding, Court Order or otherwise, which in any way directly or indirectly |
9
| restricts or prohibits you from fully performing the duties under the Appointment, in accordance with the terms and conditions of this letter. |
| 12.3 | Any notice to be given under the terms of this letter shall, in the case of notice to the Company, be deemed to be given if delivered by hand, sent by first class post to the registered office for the time being of the Company or sent by email to the Company Secretary and, in the case of notice to you, if handed to you personally, sent to your BAT email address or left at or sent by first class post to your last known address. Any such notice shall be deemed to be given at the time of its delivery to the address if delivered by hand or, if sent by first class post or e-mailed, on the next following weekday (not being a public holiday) after it was posted or e-mailed. |
| 12.4 | The benefit of each of your obligations under paragraphs 5 and 6 of this letter may be assigned to and enforced by all successors and assignees for the time being of the Company and other BAT Group companies and such agreements and obligations shall operate and remain binding notwithstanding the termination of this Appointment. |
| 12.5 | Any reference in this letter to an Act of Parliament shall be deemed to include any statutory modification or re-enactment thereof. |
| 12.6 | Otherwise than as set out elsewhere in this letter, a person who is not a party to the agreement contained in this letter shall not have any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Letter. |
| 12.7 | The terms of this Agreement are governed by and construed in accordance with the laws of England. |
| 12.8 | Without prejudice to any rights of either party to seek injunctive or declaratory relief in the Courts, and without prejudice to your statutory rights, the Company and you agree that on the occurrence of any dispute concerning interpretation or application of this Agreement, the help of the Centre for Dispute Resolution (“CEDR”) will be sought to resolve the dispute in private by means of alternative dispute resolution (“ADR”). Either party may refer the matter to CEDR in which event both parties will fully co-operate in the process which CEDR may propose. There shall be no obligation on you to continue to participate in the ADR process after 90 days from the date of referral of the dispute to CEDR. |
The terms set out in this letter represent the totality of the terms agreed between you and the Company with regard to the Appointment and supersede any previous agreements, arrangements and understandings between you and the Company.
10
Kindly confirm your agreement to the terms set out above by signing the endorsement on the enclosed copy of this letter. Please return the copy to me at the above address.
Yours sincerely
Executed as a deed by
Paul McCrory
Company Secretary
For and on behalf of
British American Tobacco p.l.c
Witnessed by
Executed as a deed by
Pedro Malan
Witnessed by
Date:
11
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/15/18 | 6-K, IRANNOTICE, S-8 | ||
| For Period end: | 12/31/17 | 11-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/09/24 British American Tobacco p.l.c. 20-F 12/31/23 244:296M 3/02/23 British American Tobacco p.l.c. 20-F 12/31/22 233:193M 7/01/22 British American Tobacco p.l.c. F-3ASR 7/01/22 13:3.3M Donnelley … Solutions/FA 3/08/22 British American Tobacco p.l.c. 20-F 12/31/21 248:128M Donnelley … Solutions/FA 3/09/21 British American Tobacco p.l.c. 20-F 12/31/20 232:119M Donnelley … Solutions/FA 7/23/18 SEC UPLOAD¶ 8/20/18 1:44K British American Tobacco p.l.c. 6/13/18 SEC UPLOAD¶ 8/20/18 1:46K British American Tobacco p.l.c. 5/16/18 SEC UPLOAD¶ 8/20/18 1:50K British American Tobacco p.l.c. |